You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Request a contact

Stay informed

Indications

Active ingredients of Incruse Ellipta 1

Incruse Ellipta 55 mcg (umeclidinium) inhalation powder.

Each single inhalation provides a delivered dose (the dose leaving the mouthpiece of the inhaler) of 55 micrograms (mcg) umeclidinium (equivalent to 65 mcg of umeclidinium bromide). This corresponds to a pre-dispensed dose of 62.5 mcg umeclidinium equivalent to 74.2 mcg umeclidinium bromide.

Incruse Ellipta Indication:

Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 1

Reference:

  1. Incruse Ellipta 55 mcg SPC; GlaxoSmithKline

POM. Further information is available from GlaxoSmithKline (Ireland) Ltd

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.

Incruse and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies